Axonics, Inc. short interest in 2024
In 2024, Axonics, Inc.'s disclosed short interest ran from 2.29% of shares outstanding on 12 Jan 2024 to 6.44% on 15 Nov 2024, a change of +4.15 percentage points. The year's high was 7.97% on 15 Apr 2024 and its low 2.29% on 12 Jan 2024, averaging 6.26% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.79 days on 30 Aug 2024. Full history: Axonics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024
2024 in figures
- Start of year
- 2.29% (12 Jan 2024)
- End of year
- 6.44% (15 Nov 2024)
- Change
- +4.15 pp
- High
- 7.97% (15 Apr 2024)
- Low
- 2.29% (12 Jan 2024)
- Average
- 6.26%
- Highest days to cover
- 14.79 (30 Aug 2024)
- SEC filings marked
- 9
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 2.29% | 1.00 | results (8-K) |
| 31 Jan 2024 | 5.29% | 1.90 | |
| 15 Feb 2024 | 5.23% | 3.19 | |
| 29 Feb 2024 | 5.57% | 3.29 | results (8-K), 10-K filed |
| 15 Mar 2024 | 5.81% | 4.55 | |
| 28 Mar 2024 | 6.79% | 3.42 | |
| 15 Apr 2024 | 7.97% | 3.34 | |
| 30 Apr 2024 | 6.68% | 5.88 | 10-Q filed, results (8-K) |
| 15 May 2024 | 7.04% | 9.91 | |
| 31 May 2024 | 6.81% | 10.49 | |
| 14 Jun 2024 | 6.62% | 10.64 | |
| 28 Jun 2024 | 6.66% | 7.84 | |
| 15 Jul 2024 | 6.35% | 12.39 | |
| 31 Jul 2024 | 6.33% | 8.95 | |
| 15 Aug 2024 | 6.43% | 9.33 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 6.80% | 14.79 | |
| 13 Sep 2024 | 6.73% | 10.73 | |
| 30 Sep 2024 | 7.05% | 8.50 | |
| 15 Oct 2024 | 6.14% | 5.50 | |
| 31 Oct 2024 | 6.48% | 9.45 | |
| 15 Nov 2024 | 6.44% | 4.55 | 10-Q filed, results (8-K) |
See also: Axonics, Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.